THE IMPACT OF PHARMACEUTICAL POLICIES ON PHARMACEUTICAL SALES PATTERNS IN SWEDEN AND JAPAN

Author(s)

Imai S1, Andersson Sundell K2, Fushimi K3
1National Hospital Organization, Tokyo, Japan, 2Sahlgrenska Academy, University of Gothenburg, Gothenburg, Japan, 3Tokyo Medical and Dental University Graduate School of Medicine, bunkyo-ku, Tokyo, Japan

OBJECTIVES Pharmaceutical expenditure accounted for between 11% to 13% of total health expenditure in European countries including Sweden in 2010 whereas this was 20% in Japan for the same year. We expect that big changes in sales pattern will happen as a result of patent expiry. Other changes have been seen when prescribers get negative/positive information on drugs. In this article we study the impact of patent expiry and negative information relating to pharmaceutical policies on pharmaceutical sales patterns of selected drugs in Sweden and Japan. METHODS we selected angiotensin-converting enzyme inhibitors (ACEs) and Angiotensin Ⅱantagonists (ARBs), since widely used in Sweden and Japan. Seasonal autoregressive integrated moving average (ARIMA) modeling with intervention analysis was used to estimate the change of sales volume. RESULTS Losartan had a positive change (0.77650, p=0.0068) in October 2010, Candesartan had a negative change (-0.50760, p=0.0058) in July 2010. There were no significant differences in the sales volume of Losartan, Telmisartan, except for Candesartan in Japan (0.04868, p=0.7995, -0.38547, p=0.0880, and -1.21215, p=0.001, respectively). In this study, we used a publication informed that Candesartan and Telmisartan had not reduced patients’ mortality by a journal July in 2009 as negative information. CONCLUSIONS We found that the sales pattern of selected drugs were changed by negative information and not by the expiry of their patents in Sweden. Whereas in Japan the negative situation for implementing generic substitution like the therapeutic substitution of Trandolapril and the possibility of switching from Candesartan to a combination drug was seen. Further assessment will be needed since factors associated with the changing use of drugs will be infinite.

Conference/Value in Health Info

2014-11, ISPOR Europe 2014, Amsterdam, The Netherlands

Value in Health, Vol. 17, No. 7 (November 2014)

Code

PCV150

Topic

Health Policy & Regulatory, Health Service Delivery & Process of Care

Topic Subcategory

Prescribing Behavior, Pricing Policy & Schemes

Disease

Cardiovascular Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×